Pharmacological adjuvants for surgical treatment of proliferative vitreoretinopathy

被引:11
作者
Scheer, S [1 ]
Morel, C [1 ]
Touzeau, O [1 ]
Laroche, L [1 ]
Sahel, JA [1 ]
机构
[1] CHNO Quinze Vingts, F-75012 Paris, France
来源
JOURNAL FRANCAIS D OPHTALMOLOGIE | 2004年 / 27卷 / 09期
关键词
proliferative vitreoretinopathy; adjuvants; retinal detachment; daunomycin; 5-fluorouracile; steroids; heparin; colchicine; 13-cis retinoic acid; silicone;
D O I
10.1016/S0181-5512(04)96264-X
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Proliferative vitreoretinopathy (PVR) is the major cause of retinal detachment surgery failure. Many adjuvants were studied in vitro and on animals, some were studied on humans. Daunomycin seems to reduce PVR recidivism. 5-FU and steroids are nontoxic but their efficacy is not clear. Heparin reduced postoperative inflammation and seems to reduce PVR recidivism when associated with 5-FU. Associating heparin and steroids seems to reduce PVR in some groups of patients (aphakic, anterior PVR). Colchicine and retinoic acid per os are ineffective, silicone oil is effective as an internal tamponade but not as an adjuvant of PVR. Currently, no molecule has proven efficacy as an adjunctive treatment of PVR.
引用
收藏
页码:1051 / 1059
页数:9
相关论文
共 50 条
  • [31] Proliferative vitreoretinopathy: Pathophysiology and clinical diagnosis
    Rouberol, F.
    Chiquet, C.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2014, 37 (07): : 557 - 565
  • [32] Biological Involvement of MicroRNAs in Proliferative Vitreoretinopathy
    Kaneko, Hiroki
    Terasaki, Hiroko
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2017, 6 (04):
  • [33] Fulminant proliferative vitreoretinopathy in syphilitic uveitis
    Queiroz R.P.
    Diniz A.V.
    Vasconcelos-Santos D.V.
    Journal of Ophthalmic Inflammation and Infection, 6 (1) : 1 - 6
  • [34] Interventions for Proliferative Vitreoretinopathy
    Wang, Wilson X.
    Xing, Maggie
    Apte, Rajendra S.
    JAMA OPHTHALMOLOGY, 2024, 142 (07) : 669 - 670
  • [35] ACLACINOMYCIN-A IN THE TREATMENT OF EXPERIMENTAL PROLIFERATIVE VITREORETINOPATHY - EFFICACY AND TOXICITY IN THE RABBIT EYE
    STEINHORST, UH
    CHEN, EP
    HATCHELL, DL
    SAMSA, GP
    SALOUPIS, PT
    WESTENDORF, J
    MACHEMER, R
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1993, 34 (05) : 1753 - 1760
  • [36] Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy
    Abu El-Asrar, Ahmed M.
    Struyf, Sofie
    Kangave, Dustan
    Geboes, Karel
    Van Damme, Jo
    EUROPEAN CYTOKINE NETWORK, 2006, 17 (03) : 155 - 165
  • [37] Challenges in proliferative vitreoretinopathy: is biological therapy a solution?
    Ferro Desideri, Lorenzo
    Zandi, Souska
    Zinkernagel, Martin S.
    Anguita, Rodrigo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (10) : 937 - 939
  • [38] PROLIFERATIVE VITREORETINOPATHY .1. CLINICOPATHOLOGICAL ISSUES
    BAUDOUIN, C
    GASTAUD, P
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 1994, 17 (12): : 789 - 799
  • [39] Retinal shortening: Ultrasonic evaluation of proliferative vitreoretinopathy
    Takkar, Brijesh
    Temkar, Shreyas
    Gaur, Nripen
    Venkatesh, Pradeep
    Chawla, Rohan
    Kumar, Atul
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2017, 65 (11) : 1172 - 1177
  • [40] SUBRETINAL MEMBRANES IN PROLIFERATIVE VITREORETINOPATHY - AN IMMUNOHISTOCHEMICAL STUDY
    GARCIAARUMI, J
    CORCOSTEGUI, B
    TALLADA, N
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 1992, 12 (03): : S55 - S59